Last update 11 Oct 2025

GLB-002

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
GLB 002, GLB A062 B, GLB-002
+ [2]
Target
IKZF1 x IKZF3
Action
degraders
Mechanism
IKZF1 degraders(DNA-binding protein Ikaros degraders), IKZF3 degraders(Zinc finger protein Aiolos degraders)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Diffuse Large B-Cell LymphomaMantle-Cell LymphomaMarginal Zone B-Cell Lymphoma+ [4]
Inactive Indication-
Originator Organization
Glubio Pharmaceutical Co. Ltd.
Active Organization
Glubio Pharmaceutical Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with GLB-002
NCT06219356
/ RecruitingPhase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
100 Clinical Results associated with GLB-002
Login to view more data
100 Translational Medicine associated with GLB-002
Login to view more data
100 Patents (Medical) associated with GLB-002
Login to view more data
100 Deals associated with GLB-002
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 1
China
Glubio Pharmaceutical Co. Ltd.
11 Jan 2024
Mantle-Cell LymphomaPhase 1
China
Glubio Pharmaceutical Co. Ltd.
11 Jan 2024
Marginal Zone B-Cell LymphomaPhase 1
China
Glubio Pharmaceutical Co. Ltd.
11 Jan 2024
Peripheral T-Cell LymphomaPhase 1
China
Glubio Pharmaceutical Co. Ltd.
11 Jan 2024
Recurrent Grade 3b Follicular LymphomaPhase 1
China
Glubio Pharmaceutical Co. Ltd.
11 Jan 2024
Multiple MyelomaPhase 1
China
Glubio Pharmaceutical Co. Ltd.
05 Jan 2024
Hematologic NeoplasmsIND Approval
China
Glubio Pharmaceutical Co. Ltd.
07 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free